Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cardiff Oncology Inc

CRDF
Current price
4.59 USD -0.66 USD (-12.57%)
Last closed 5.28 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 250 639 104 USD
Yield for 12 month +203.97 %
1Y
3Y
5Y
10Y
15Y
CRDF
21.11.2021 - 28.11.2021

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Address: 11055 Flintkote Avenue, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.5 USD

P/E ratio

Dividend Yield

Current Year

+488 000 USD

Last Year

+386 000 USD

Current Quarter

+156 000 USD

Last Quarter

+141 000 USD

Current Year

+90 000 USD

Last Year

+186 000 USD

Current Quarter

+53 000 USD

Last Quarter

+34 000 USD

Key Figures CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -45 014 000 USD
Operating Margin TTM -6623.08 %
PE Ratio
Return On Assets TTM -28.69 %
PEG Ratio
Return On Equity TTM -47.07 %
Wall Street Target Price 10.5 USD
Revenue TTM 488 000 USD
Book Value 1.56 USD
Revenue Per Share TTM 0.011 USD
Dividend Share
Quarterly Revenue Growth YOY 21.9 %
Dividend Yield
Gross Profit TTM -26 721 000 USD
Earnings Share -0.93 USD
Diluted Eps TTM -0.93 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRDF

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:6
Payout Ratio
Last Split Date 20.02.2019
Dividend Date 20.02.2019

Stock Valuation CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 362.8512
Price Sales TTM 513.6047
Enterprise Value EBITDA -3.9337
Price Book MRQ 3.5811

Financials CRDF

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRDF

For 52 weeks

0.94 USD 6.42 USD
50 Day MA 3.71 USD
Shares Short Prior Month 2 813 413
200 Day MA 2.03 USD
Short Ratio 0.79
Shares Short 3 410 807
Short Percent 7.86 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics